Cessation of secondary prophylaxis in patients with cryptococcosis

AIDS

Volumn 15, Issue 11, 2001, Pages 1438-1439

  Nwokolo, Nneka C ^a   Fisher, Martin ^b   Gazzard, Brian G ^a   Nelson, Mark R ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE; FUNGUS ANTIGEN; ITRACONAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0035958771     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00015     Document Type: Article

References (11)

1. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort study
2. Is it safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: Results from eight prospective European cohorts
3. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 count following highly active anti-retroviral therapy
4. Discontinuation of toxoplasmic encephalitis prophylaxis is safe in HIV-1 and T. gondii co-infected patients after immunological recovery with HAART: Preliminary results of the GESIDA 04/98-B study
5. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
6. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
7. Discontinuation of antifungal therapy for cryptococcosis after immunological response to antiretroviral therapy
8. Discontinuation of secondary prophylaxis for cryptococcal meningitis in AIDS patients receiving HAART
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Changing patterns of mortality across Europe in patients infected with HIV-1
11. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy